The method could help predict whether immunotherapies will work in a patient or how a tumor will respond to drug treatment.

New research on a cytokine called IL-17 adds to growing evidence that immune molecules can influence behavior during illness.

When his son received a devastating diagnosis, Fernando Goldsztein MBA ’03 founded an initiative to help him and others.

The nanoparticle-based vaccine shows promise against many variants of SARS-CoV-2, as well as related sarbecoviruses that could jump to humans.

By examining antigen architectures, MIT researchers built a therapeutic cancer vaccine that may improve tumor response to immune checkpoint blockade treatments.

MIT researchers find that the first dose primes the immune system, helping it to generate a strong response to the second dose, a week later.

MIT scientists’ discovery yields a potent immune response, could be used to develop a potential tumor vaccine.

A chip the size of a pack of cards uses fewer resources and a smaller footprint than existing automated manufacturing platforms and could lead to more affordable cell therapy manufacturing.

The building will serve as a hub for research on the development of immunology-based treatments.

With support from The Marcus Foundation, an MIT neuroscientist and a Harvard Medical School immunologist will study the “fever effect” in an effort to devise therapies that mimic its beneficial effects.